

## PRESS RELEASE

## Changes in the Group's Scientific Division and appointment of the CEO of Collectis Plant Sciences

**Paris, January 30th, 2012 – Collectis (Alternext: ALCLS), the French genome engineering specialist, is announcing the operational withdrawal of Frédéric Pâques, who has joined the Group's Scientific Advisory Board, as well as three appointments in its Scientific Division: Jean-Charles Epinat as Chief Technology Officer, Philippe Duchâteau as Chief Scientific Officer, and Frédéric Cédrone as Platform Director. Alongside this, Luc Mathis has been appointed CEO of Collectis Plant Sciences, a Collectis subsidiary.**

**Jean-Charles Epinat** has been appointed as Collectis' Chief Technology Officer, joining the Company's executive committee. With a PhD in science, he carried out his postdoctoral fellowship at Boston University (Massachusetts, USA), before moving to the Institut Pasteur. After joining Collectis in 2000, he was appointed to head up the Group's technical platform in 2005. His achievements include the development of selection and screening methods for the activity of meganucleases in yeast that are still applied today.

**Philippe Duchateau** has been appointed Chief Scientific Officer. With a PhD in science, Philippe Duchateau joined Collectis in 2001 after nine years with the University of California's Cardiovascular Research Institute (San Francisco, USA). Since 2004, he was in charge of Collectis' research department. He is taking over from Frédéric Pâques, who the Group pays tribute to for the work accomplished in this position since 2002.

**Frédéric Pâques**, who graduated from École Normale Supérieure de Paris and has a PhD in science, began his career at Brandeis University (Massachusetts, USA), before joining the CNRS' (Paris) Institut Jacques Monod in 1999. Appointed as Collectis' Chief Scientific Officer in 2002, Frédéric Pâques has been behind the design and deployment of the mass screening tools which have made a key contribution towards Collectis' scientific success. His work has been recognized in 40 scientific journals with review boards. Frédéric Pâques is joining Collectis' Scientific Advisory Board shortly, taking on extensive responsibilities.

Lastly, **Luc Mathis** is being appointed CEO of Collectis Plant Sciences, Collectis' American subsidiary, specialized in developing genome engineering solutions for agribusiness. With a PhD in science, he began his career with the Institut Pasteur (2001-2005), before joining Collectis in 2006. He had previously taken on more and more extensive responsibilities as the business - now Collectis Plant Sciences - grew, becoming head of development.

### About Collectis

Collectis improves life by applying its genome engineering expertise to a broad range of applications, including human therapeutics, biological research and agriculture. Collectis is listed on the NYSE-Euronext Paris Alternext market (code: ALCLS).

To find out more, visit [www.collectis.com](http://www.collectis.com).

**Disclaimer**

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Collectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

**For further information, please contact:**

Philippe Valachs  
Company Secretary  
Tel: +33 (0)1 81 69 16 00  
[media@collectis.com](mailto:media@collectis.com)

Calyptus  
Alexis Breton / Cyril Combe  
Tel: +33 (0)1 53 65 68 68  
[collectis@calyptus.net](mailto:collectis@calyptus.net)